ArticleDrugs in R&D2023

Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation.

André B P van Kuilenburg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.